Anticoagulant treatment with phenprocoumon is challenging because of the narrow therapeutic range and the wide inter- and intra-patient variability in dose response. Frequent monitoring of the international normalized ratio (INR) is therefore required. Polymorphisms in two genes, CYP2C9 and VKORC1 explain approximately one third of the variation in dose requirements [1-3]. CYP2C9 encodes the main metabolizing enzyme of coumarins, the cytochrome P450 2C9 enzyme (CYP2C9), while VKORC1 encodes the pharmacodynamic target enzyme for coumarins, vitamin K epoxide reductase multiprotein complex 1 (VKORC1). [...]

Additional Metadata
Keywords Coumarins, CYP2C9, International Normalized Ratio, Pharmacogenetics, VKORC1
Persistent URL dx.doi.org/10.1111/jth.12007, hdl.handle.net/1765/38338
Journal Journal of Thrombosis and Haemostasis
Note Accepted Author Manuscript
Grant This work was funded by the European Commission 7th Framework Programme; grant id fp7/223062 - A pharmacogenomic approach to coumarin anticoagulant therapy (EU-PACT)
Citation
Verhoef, T.I, Redekop, W.K, Hegazy, H, de Boer, A.C, & Maitland-van der Zee, A-H. (2012). Long-term anticoagulant effects of CYP2C9 and VKORC1 genotypes in phenprocoumon users. Journal of Thrombosis and Haemostasis, 10(12), 2610–2612. doi:10.1111/jth.12007